Semantic Scholar uses AI to extract papers important to this topic.
TB-402 is a long-acting monoclonal antibody that partially inhibits factor VIII. A single administration of TB-402 was effective… Expand Summary. Background: TB‐402 is a partially inhibiting antibody of factor VIII that is under development as a long‐acting… Expand INTRODUCTION
Partial inhibition of Factor VIII (FVIII) may provide antithrombotic efficacy whilst avoiding excessive… Expand Summary. Background: TB‐402 is a novel anticoagulant monoclonal antibody with a prolonged antithrombotic effect resulting from… Expand The therapeutic armamentarium of parenteral anticoagulants available to clinicians is mainly composed by unfractionated heparin… Expand BACKGROUND
TB-402, a human monoclonal antibody that partially inhibits Factor VIII activity (FVIII:C), is being developed as a… Expand Total VTE was lower in each of the TB-402 groups compared to the enoxaparin group: 16.7% (9.8-26.9), 23.9% (15.3-35.3), 24.1%(16… Expand